CytRx Operating Income

CytRx (CYTR) currently reports a operating income of $-3.5B as of March 2025. That compares with $-7.7B in the prior-year period — up 54.2% year over year. Use the charts on this page to explore CytRx's operating income history and peer comparisons.

CytRx's operating income increased from $-7.7B to $-3.5B — a 54.2% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytRx reported $-3.5B in operating income as of March 2025. That compares with $-7.7B in the prior-year period — up 54.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-3.5B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CytRx, and consider following CYTR for alerts when major investors trade the stock.

CytRx is classified in the Healthcare sector. On operating income, it currently shows $-3.5B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTR with unrelated industries.